Contact Us
Make My Homepage

Merck’s 2nd Quarter profit more than doubles

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double second-quarter profit, improve its profit forecast and top analysts’ expectations.

The maker of popular Type 2 diabetes pill Januvia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

Merck scientist Pascale Nantermet conducting 2013 research on HIV last year. Merck reports quarterly financial results on Tuesday, July 29, 2014. (AP Photo/Matt Rourke)

Merck, based in Whitehouse Station, New Jersey, said its earnings, adjusted for one-time gains and costs, were 85 cents per share. Analysts surveyed by Zacks Investment Research expected 81 cents.

Merck recorded a $741 million gain from AstraZeneca PLC, which exercised its option to buy out Merck’s interest in the British drugmaker’s heartburn drugs Nexium and Prilosec.

The world’s fourth-biggest drugmaker’s revenue fell 1 percent to $10.93 billion, still $220 million above Wall Street expectations.

CEO Kenneth Frazier said on a conference call that Merck favors smaller acquisitions – like its $3.85 billion purchase of hepatitis C treatment developer Idenix Pharmaceuticals Inc., expected to close this quarter – and is not looking for a deal enabling it to move its legal headquarters to a country with a lower tax rate.

That strategy, called inversion, is suddenly hot in corporate America. The U.S. has the world’s highest corporate tax rate, 35 percent, but pharmaceutical companies here generally pay well under 30 percent.

Chicago-based drugmaker AbbVie Inc. just reached a $55 billion deal to combine with British counterpart Shire PLC and incorporate in Britain.

BernsteinResearch analyst Dr. Timothy Anderson wrote to investors that Merck “will likely have another flattish year in 2014 in terms of financial performance but then growth should return more consistently.”

Merck noted it expects by early next year to launch two new drugs awaiting approval: long-delayed suvorexant for insomnia and pembrolizumab for advanced melanoma. The latter is part of the promising new class of drugs that stimulate the immune system to identify and attack cancer cells.

Meanwhile, Merck got U.S. approval in April for two tablets to gradually reduce grass and ragweed allergies, and in May for anticlotting drug Zontivity.

Sales of Merck’s prescription drugs fell 2 percent to $9.09 billion. Top sellers were Type 2 diabetes pills Januvia and Janumet, up 2 percent at $1.58 billion, and cholesterol medicines Zetia and Vytorin, up 6 percent to a combined $1.13 billion.

Merck’s consumer health segment had the biggest sales increase, up 19 percent to $583 million. In May, Merck agreed to sell that to Germany’s Bayer for $14.2 billion. It includes Claritin and the Coppertone sun-care line.

Merck said it expects full-year sales of $42.4 billion to $43.2 billion and profit of $3.43 to $3.53 per share, excluding one-time items. In January, it forecast $3.35 to $3.53.

In morning trading, Merck shares were up 72 cents at $58.69. They have increased 20 percent in the last 12 months.

Follow Linda A. Johnson at http://www.twitter.com/LindaJ-onPharma .

© 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use.

Best of the Web


Leave a Comment

It appears that you already have an account created within our VIP network of sites on . To keep your points and personal information safe, we need to verify that it's really you. To activate your account, please confirm your password. When you have confirmed your password, you will be able to log in through Facebook on both sites.

Forgot your password?

*Please note that your points, prizes and activities will not be shared between programs within our VIP network.

It appears that you already have an account on this site associated with . To connect your existing account with your Facebook account, just click on the account activation button below. You will maintain your existing profile and VIP program points. After you do this, you will be able to always log in to http://nj1015.com using your Facebook account.

*Please note that your points, prizes and activities will not be shared between programs within our VIP network.

Please fill out the information below to help us provide you a better experience.

Register on New Jersey 101.5 quickly by logging in with your Facebook account. It's just as secure, and no password to remember!

Not a Member? Sign Up Here

Register on New Jersey 101.5 quickly by logging in with your Facebook account. It's just as secure, and no password to remember!